EU-101

N/A

Report date: 2022/10/26 15:47:44

Base Information

Drug NameEU-101
Drug Alias NameEU-101NOV-1801
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsCD8-positive T-Lymphocytes stimulantsTumor necrosis factor receptor superfamily member 9 agonists
TargetsTumor necrosis factor receptor superfamily member 9
Therapy Area/IndicationsSolid tumoursProstatic NeoplasmsCarcinoma, Non-Small-Cell Lung +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth Korea
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesEutilex
China Registration ClassN/A

Develop Information

Active CompaniesEutilexZhejiang Huahai Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursProstatic NeoplasmsCarcinoma, Non-Small-Cell Lung +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A